Evidence map›Paper›PMID 35414110›Full record

ArticleMobile DNA2022

RNA sensor MDA5 suppresses LINE-1 retrotransposition by regulating the promoter activity of LINE-1 5'-UTR.

Jiaxiu Yan, Yifei Zhao, Juan Du, Yu Wang, Shaohua Wang, Qing Wang, Xu Zhao, Wei Xu, Ke Zhao

Open access · goldAbstract read
In one paragraph

Article in Mobile DNA, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. BeyondInternational journal of molecular sciences · 2025
    Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jiaxiu Yan *Institute of Virology and AIDS Research, First Hospital of Jilin University, Changchun, Jilin, China.
Yifei Zhao *Institute of Virology and AIDS Research, First Hospital of Jilin University, Changchun, Jilin, China.
Juan DuInstitute of Virology and AIDS Research, First Hospital of Jilin University, Changchun, Jilin, China.
Yu WangInstitute of Virology and AIDS Research, First Hospital of Jilin University, Changchun, Jilin, China.
Shaohua WangInstitute of Virology and AIDS Research, First Hospital of Jilin University, Changchun, Jilin, China.
Qing WangInstitute of Virology and AIDS Research, First Hospital of Jilin University, Changchun, Jilin, China.
Xu ZhaoInstitute of Virology and AIDS Research, First Hospital of Jilin University, Changchun, Jilin, China.
Wei XuDepartment of Clinical Laboratory, First Hospital of Jilin University, Changchun, Jilin, China. xu_w@jlu.edu.cn.
Ke ZhaoInstitute of Virology and AIDS Research, First Hospital of Jilin University, Changchun, Jilin, China. zhaoke@jlu.edu.cn.ORCID http://orcid.org/0000-0002-5833-1852
Jilin University · CN

Funding

China Postdoctoral Science Foundation 2020M670843Fundamental Research Funds for the Central Universities 2017TD-08Key Laboratory of Molecular Virology, Jilin Province 20102209National Natural Science Foundation of China 32100108National Natural Science Foundation of China 32170140National Natural Science Foundation of China 32170146National Natural Science Foundation of China 81601363National Natural Science Foundation of China 81902049Science and Technology Department of Jilin Province 20200201525JCthe First Hospital of Jilin University 2020-CXQ-02the First Hospital of Jilin University 2020JC03the First Hospital of Jilin University JDYY102019015the Norman Bethune Health Science Centre of Jilin University 2018B18
6 · The paper itself

Abstract

backgroundType 1 long interspersed elements, or LINE-1, are the only retroelements that replicate autonomously in human cells. The retrotransposition process of LINE-1 can trigger the activation of the innate immune system and has been proposed to play a role in the development of several autoimmune diseases, including Aicardi-Goutières syndrome (AGS). In contrast, all known AGS-associated proteins, except MDA5, have been reported to affect LINE-1 activity. Thus, MDA5 is likely to also function as a LINE-1 suppressor.

resultsMDA5 was found to potently suppress LINE-1 activity in a reporter-based LINE-1 retrotransposition assay. Although MDA5 is an endogenous RNA sensor able to activate the innate immune system, increased interferon (IFN) expression only contributed in part to MDA5-mediated LINE-1 suppression. Instead, MDA5 potently regulated the promoter activity of LINE-1 5'-UTR, as confirmed by transiently expressed myc-tagged MDA5 or knockdown of endogenous MDA5 expression. Consequently, MDA5 effectively reduced the generation of LINE-1 RNA and the subsequent expression of LINE-1 ORF1p and ORF2p. Interestingly, despite MDA5 being a multi-domain protein, the N-terminal 2CARD domain alone is sufficient to interact with LINE-1 5'-UTR and inhibit LINE-1 promoter activity.

conclusionOur data reveal that MDA5 functions as a promoter regulator; it directly binds to the LINE-1 5'-UTR and suppresses its promoter activity. Consequently, MDA5 reduces LINE-1 RNA and protein levels, and ultimately inhibits LINE-1 retrotransposition. In contrast, MDA5-induced IFN expression only plays a mild role in MDA5-mediated LINE-1 suppression. In addition, the N-terminal 2CARD domain was found to be a functional region for MDA5 upon inhibition of LINE-1 replication. Thus, our data suggest that besides being an initiator of the innate immune system, MDA5 is also an effector against LINE-1 activity, potentially forming a feedback loop by suppressing LINE-1-induced innate immune activation.

Indexed as

5′-UTRLINE-1MDA5Promoter regulationRetrotransposition

Identifiers

PMID35414110
PMCPMC9003951
OpenAlexW4226154687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.